[Prostatic carcinoma: metabolic effect of percutaneous beta-estradiol (author's transl)].
Twenty one patients suffering from carcinoma of the prostate, confirmed histologically and previously untreated, received treatment in the form of 17 beta-estradiol administered percutaneously. At a dose of 6 mg of estradiol per day, testosterone levels fell to a mean of 1 ng/ml. No change in lipids, lipoproteins nor cholinesterase were detected.
D000287:Administration, Topical; D004958:Estradiol / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D013739:Testosterone / Q000097:blood
D013739:Testosterone; D004958:Estradiol
Cancer de la prostate: effets métaboliques des bêta-estradiol par voie percutanée.